Conversely to what was expected from the tumor-promoting action of basigin, we observed a down-regulation/expression of basigin in the deep region of the tumor, which appeared associated with variations in interactors different from CD44, such as GaL-3, identified as a less-abundant protein in the deep area of the tumor. The gene discussed is CD44; the disease is neoplasm.